Standish M. Fleming of Forward Ventures specializes in venture capital investing, mainly in biopharmaceuticals. He invests in early clinical-stage assets and he has founded a number of companies. Generally, he invests in early venture rounds but in fairly mature technologies that are already in clinical testing and in the case of medical devices often in marketed products. He does have some concerns;
“What is probably the biggest long-term threat to the sustainability of the bio-venture market is an ongoing and permanent dislocation between pricing and underlying values, whether the values are too high or too low. That creates an environment in which we cannot reliably invest in and build these companies over the extended period of time that we need to bring a new pharmaceutical to market.”
Going forward he also has some concerns
“It takes a cost of $2.1 billion to bring a new molecule to market today. That price continues to grow at a geometric rate. If people cannot reasonably expect to recoup that kind of investment, they are simply not going to make it. Innovation is going to be the first thing to die in the pharmaceutical world. We can lose generations of potential new drugs here and destroy an infrastructure that we may never be able to rebuild.”
PDL BioPharma (PDLI) Closes Revenue-Generating Deal with AxoGen (OTC:AXGN)
October 10, 2012
Sanj K. Patel, President and CEO of Synageva BioPharma Corp. (GEVA), Presents at the Canaccord Genuity Growth
August 15, 2014
Invesco Mortgage Capital (IVR) and American Capital Mortgage (MTGE) Favored as Hybrid, Prepay-Protected REITs
November 02, 2012
BDCs Triangle Capital (TCAP), Medley Capital (MCC) and THL Credit (THL) Profit in the Lower Middle Market
December 18, 2012
Solar Capital Ltd. (SLRC) Strengthens Balance Sheet by Accessing Longer-Term Capital
April 05, 2013
